Workflow
cocoa
icon
Search documents
X @The Economist
The Economist· 2025-08-23 05:20
Growing plant cells such as cocoa is cheaper and easier than growing animal tissue, according to one investor https://t.co/m4LwAER0F2 ...
HEALTH BENEFIT OF DARK CHOCOLATE YOU HAVE NO IDEA ABOUT
The Diary Of A CEO· 2025-08-13 19:06
Dark chocolate is a medicine end of one of the best medicines around is 50 grams to 100 grams of 75% or more dark chocolate. Do you know what I've just realized. My girlfriend, she's going to live till she's 150 because she all she eats 90% or something 80% dark chocolate.She drinks green tea all day. She should be stepping in for you. Seriously.Brain health as well. Mhm. cardiovascular health.I mean they just they do studies where they've put cocoa into volunteers and they were able to show changes in the ...
X @Bloomberg
Bloomberg· 2025-08-11 15:20
Company Overview - A French trader of cocoa, coffee and spices, with origins dating back to 1848, is for sale [1] Financial Performance - Profit jumped more than 1,000% [1]
X @Bloomberg
Bloomberg· 2025-08-02 08:08
Market Trends - A famed oil trader Pierre Andurand has pulled back from a bullish bet on cocoa [1] - A series of mistimed trades led to deep losses in cocoa market [1]
Archer-Daniels-Midland: Undervalued Agricultural Giant Poised For Recovery
Seeking Alpha· 2025-05-27 09:43
Company Overview - Archer-Daniels-Midland Company (NYSE: ADM) is involved in the production of oilseeds, corn, wheat, cocoa, and other agricultural commodities [1] - ADM is one of the four major companies dominating the global grain market, alongside Cargill, Louis Dreyfus, and Bunge [1] Investment Analysis Approach - The company specializes in analyzing US bonds and commodities, with a focus on medium to long-term investment horizons while also considering short-term price movements [1] - The typical research process includes identifying undervalued or overvalued assets, reviewing fundamentals, and assessing technical and economic signals if the fundamentals yield meaningful results [1] - The analysis is primarily value-driven and contrarian, focusing on mispriced assets [1]
Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion
Globenewswire· 2025-05-15 11:00
Core Insights - Pluri Inc. aims to lead a global biotech revolution in healthcare, food, and agriculture through its innovative cell expansion platform, which allows for the production of pharmaceuticals, food products, and agricultural goods to address multi-billion dollar markets [1][10] Business Developments - The company anticipates a significant turning point in the upcoming fiscal year by unlocking the potential of its cell expansion technology, particularly in the cocoa and coffee industries, which are facing shortages due to climate change and rising demand [2][9] - Pluri has strengthened its position in the cultivated cacao space by partnering with an Israeli AgFoodTech company that is developing cell-based cacao technology, addressing challenges in the global cacao industry [3][10] - The company has secured additional investment from a new strategic partner with expertise in healthcare, enhancing its financial position and ability to expand into key geographies [4][10] Financial Performance - In the first nine months of fiscal year 2025, Pluri recorded a fourfold increase in revenue, rising from $230,000 in the same period of fiscal year 2024 to $938,000, driven by its CDMO and AgTech businesses [7][8] - The company is advancing new food tech partnerships and licensing opportunities, contributing to its revenue growth [8][10] Strategic Initiatives - Pluri holds a 69% stake in Ever After Foods Ltd., which utilizes its cell expansion technology for cultivated meat production, with significant funding rounds supporting this initiative [5][10] - The company is actively discussing commercial implementation opportunities with leading players in the cocoa and coffee industries, including potential out-licensing to strategic partners [9][10] Research and Development - Pluri has received $2.2 million in funding from the U.S. National Institutes of Health and the Department of Defense for the development of PLX-R18 for treating Acute Radiation Syndrome, although this funding has been discontinued due to federal budget cuts [6][10]